Wide diagnostic and genotypic spectrum in patients with suspected mitochondrial disease.
Genetic diagnosis
Mitochondrial disease
Next generation sequencing
Variants
Whole exome sequencing
mtDNA
nDNA
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
02 10 2023
02 10 2023
Historique:
received:
25
04
2023
accepted:
21
09
2023
medline:
4
10
2023
pubmed:
3
10
2023
entrez:
2
10
2023
Statut:
epublish
Résumé
Mitochondrial Diseases (MDs) are a diverse group of neurometabolic disorders characterized by impaired mitochondrial oxidative phosphorylation and caused by pathogenic variants in more than 400 genes. The implementation of next-generation sequencing (NGS) technologies helps to increase the understanding of molecular basis and diagnostic yield of these conditions. The purpose of the study was to investigate diagnostic and genotypic spectrum in patients with suspected MD. The comprehensive analysis of mtDNA variants using Sanger sequencing was performed in the group of 83 unrelated individuals with clinically suspected mitochondrial disease. Additionally, targeted next generation sequencing or whole exome sequencing (WES) was performed for 30 patients of the study group. The overall diagnostic rate was 21.7% for the patients with suspected MD, increasing to 36.7% in the group of patients where NGS methods were applied. Mitochondrial disease was confirmed in 11 patients (13.3%), including few classical mitochondrial syndromes (MELAS, MERRF, Leigh and Kearns-Sayre syndrome) caused by pathogenic mtDNA variants (8.4%) and MDs caused by pathogenic variants in five nDNA genes. Other neuromuscular diseases caused by pathogenic variants in seven nDNA genes, were confirmed in seven patients (23.3%). The wide spectrum of identified rare mitochondrial or neurodevelopmental diseases proves that MD suspected patients would mostly benefit from an extensive genetic profiling allowing rapid diagnostics and improving the care of these patients.
Sections du résumé
BACKGROUND
Mitochondrial Diseases (MDs) are a diverse group of neurometabolic disorders characterized by impaired mitochondrial oxidative phosphorylation and caused by pathogenic variants in more than 400 genes. The implementation of next-generation sequencing (NGS) technologies helps to increase the understanding of molecular basis and diagnostic yield of these conditions. The purpose of the study was to investigate diagnostic and genotypic spectrum in patients with suspected MD. The comprehensive analysis of mtDNA variants using Sanger sequencing was performed in the group of 83 unrelated individuals with clinically suspected mitochondrial disease. Additionally, targeted next generation sequencing or whole exome sequencing (WES) was performed for 30 patients of the study group.
RESULTS
The overall diagnostic rate was 21.7% for the patients with suspected MD, increasing to 36.7% in the group of patients where NGS methods were applied. Mitochondrial disease was confirmed in 11 patients (13.3%), including few classical mitochondrial syndromes (MELAS, MERRF, Leigh and Kearns-Sayre syndrome) caused by pathogenic mtDNA variants (8.4%) and MDs caused by pathogenic variants in five nDNA genes. Other neuromuscular diseases caused by pathogenic variants in seven nDNA genes, were confirmed in seven patients (23.3%).
CONCLUSION
The wide spectrum of identified rare mitochondrial or neurodevelopmental diseases proves that MD suspected patients would mostly benefit from an extensive genetic profiling allowing rapid diagnostics and improving the care of these patients.
Identifiants
pubmed: 37784170
doi: 10.1186/s13023-023-02921-0
pii: 10.1186/s13023-023-02921-0
pmc: PMC10544509
doi:
Substances chimiques
DNA, Mitochondrial
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
307Informations de copyright
© 2023. Institut National de la Santé et de la Recherche Médicale (INSERM).
Références
Hum Mutat. 2015 Mar;36(3):301-6
pubmed: 25512002
Curr Protoc Bioinformatics. 2016 Jun 20;54:1.30.1-1.30.33
pubmed: 27322403
PLoS Comput Biol. 2010 Dec 02;6(12):e1001025
pubmed: 21152010
Genome Med. 2022 Apr 5;14(1):38
pubmed: 35379322
PLoS Comput Biol. 2017 Jun 22;13(6):e1005628
pubmed: 28640805
Am J Med Genet A. 2018 May;176(5):1232-1237
pubmed: 29681094
J Transl Med. 2016 Jun 12;14(1):174
pubmed: 27290639
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
Genome Res. 1999 Aug;9(8):677-9
pubmed: 10447503
Mol Genet Genomic Med. 2023 Jan;11(1):e2059
pubmed: 36181358
Nat Rev Dis Primers. 2016 Oct 20;2:16080
pubmed: 27775730
J Inherit Metab Dis. 2021 Jan;44(1):22-41
pubmed: 32618366
Neurol Genet. 2023 Apr 10;9(3):e200068
pubmed: 37057294
Hum Mutat. 2020 Dec;41(12):2028-2057
pubmed: 32906214
Genet Med. 2020 Jul;22(7):1254-1261
pubmed: 32313153
Nucleic Acids Res. 2021 Jan 8;49(D1):D1541-D1547
pubmed: 33174596
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Neurol Genet. 2021 May 25;7(3):e597
pubmed: 34056100
Nucleic Acids Res. 2017 Jan 4;45(D1):D840-D845
pubmed: 27899611
Neurology. 2002 Nov 12;59(9):1402-5
pubmed: 12427891
Front Genet. 2018 Dec 11;9:632
pubmed: 30619459
PLoS Comput Biol. 2017 Dec 11;13(12):e1005867
pubmed: 29227991
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Mol Genet Metab. 2020 Sep - Oct;131(1-2):66-82
pubmed: 32980267
Front Mol Biosci. 2020 Nov 02;7:590842
pubmed: 33240932
Mol Genet Metab Rep. 2018 Mar 15;15:80-89
pubmed: 30009132
BMC Med Genet. 2018 Apr 7;19(1):57
pubmed: 29625556
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Orphanet J Rare Dis. 2022 Feb 19;17(1):60
pubmed: 35183220
J Clin Invest. 2022 Apr 1;132(7):
pubmed: 35362483
Nucleic Acids Res. 2019 Jan 8;47(D1):D886-D894
pubmed: 30371827
Neurology. 2006 Nov 28;67(10):1823-6
pubmed: 17130416
Nat Rev Neurol. 2021 Apr;17(4):215-230
pubmed: 33623159
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
EBioMedicine. 2020 Jun;56:102784
pubmed: 32454403
Hum Mutat. 2015 Feb;36(2):E2413-22
pubmed: 25516408
Genet Med. 2018 Apr;20(4):444-451
pubmed: 29261183
Nucleic Acids Res. 2019 Jan 8;47(D1):D1202-D1210
pubmed: 30371888
Bioinformatics. 2019 Jun 1;35(11):1978-1980
pubmed: 30376034
Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067
pubmed: 29165669
Nat Protoc. 2009;4(7):1073-81
pubmed: 19561590
Expert Rev Mol Diagn. 2020 Oct;20(10):1003-1008
pubmed: 32902337
Nat Commun. 2017 Jun 12;8:15824
pubmed: 28604674